Species differences in hepatic and intestinal metabolic activities for 43 human cytochrome P450 substrates between humans and rats or dogs

References

• Aiba T, Takehara Y, Okuno M, Hashimoto Y. (2003). Poor correlation between intestinal and hepatic metabolic rates of CYP3A4 substrates in rats. Pharm Res 20:745–8
   PubMed Web of Science ®Google Scholar
• Chow T, Imaoka S, Hiroi T, Funae Y. (1999). Developmental changes in the catalytic activity and expression of CYP2D isoforms in the rat liver. Drug Metab Dispos 27:188–92
   PubMed Web of Science ®Google Scholar
• Dedrick RL. (1973). Animal scale-up. J Pharmacokinet Biopharm 1:435–61
   PubMedGoogle Scholar
• Faber MS, Jetter A, Fuhr U. (2005). Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin Pharmacol Toxicol 97:125–34
   PubMed Web of Science ®Google Scholar
• Hiroi T, Imaoka S, Chow T, Funae Y. (1998). Tissue distributions of CYP2D1, 2D2, 2D3 and 2D4 mRNA in rats detected by RT-PCR. Biochim Biophys Acta 1380:305–12
   PubMed Web of Science ®Google Scholar
• Hosea NA, Collard WT, Cole S, et al. (2009). Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J Clin Pharmacol 49:513–33
   PubMed Web of Science ®Google Scholar
• Houston JB. (1994). Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469–79
   PubMed Web of Science ®Google Scholar
• Iwatsubo T, Hirota N, Ooie T, et al. (1997). Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 73:147–71
   PubMed Web of Science ®Google Scholar
• Komura H, Iwaki M. (2008). Species differences in in vitro and in vivo small intestinal metabolism of CYP3A substrates. Pharm Sci 97:1775–800
   PubMed Web of Science ®Google Scholar
• Lewis DF. (2003). Human cytochromes P450 associated with the phase 1 metabolism of drugs and other xenobiotics: a compilation of substrates and inhibitors of the CYP1, CYP2 and CYP3 families. Curr Med Chem 10:1955–72
   PubMed Web of Science ®Google Scholar
• Lindell M, Lang M, Lennernäs H. (2003). Expression of genes encoding for drug metabolising cytochrome P450 enzymes and P-glycoprotein in the rat small intestine; comparison to the liver. Eur J Drug Metab Pharmacokinet 28:41–8
   PubMed Web of Science ®Google Scholar
• Lisitsa A, Archakov A, Lewi P, Janssen P. (2003). Bioinformatic insight into the unity and diversity of cytochromes P450. Methods Find Exp Clin Pharmacol 25:733–45
   PubMedGoogle Scholar
• Martignoni M, Groothuis GM, de Kanter R. (2006). Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2:875–94
   PubMed Web of Science ®Google Scholar
• Matsubara T, Kim HJ, Miyata M, et al. (2004). Isolation and characterization of a new major intestinal CYP3A form, CYP3A62, in the rat. J Pharmacol Exp Ther 309:1282–90
   PubMed Web of Science ®Google Scholar
• Mealey KL, Jabbes M, Spencer E, Akey JM. (2008). Differential expression of CYP3A12 and CYP3A26 mRNAs in canine liver and intestine. Xenobiotica 38:1305–12
   PubMed Web of Science ®Google Scholar
• Mitschke D, Reichel A, Fricker G, Moenning U. (2008). Characterization of cytochrome P450 protein expression along the entire length of the intestine of male and female rats. Drug Metab Dispos 36:1039–45
   PubMed Web of Science ®Google Scholar
• Mordenti J. (1986). Man versus beast: pharmacokinetic scaling in mammals. J Pharm Sci 75:1028–40
   PubMed Web of Science ®Google Scholar
• Nakamoto T, Oda Y, Imaoka S, et al. (1997). Effect of phenobarbital on the pharmacokinetics of lidocaine, monoethylglycinexylidide and 3-hydroxylidocaine in the rat: correlation with P450 isoform levels. Drug Metab Dispos 1997:296–300
   Google Scholar
• Nishimuta H, Sato K, Mizuki Y, et al. (2010). Prediction of the intestinal first-pass metabolism of CYP3A substrates in humans using cynomolgus monkeys. Drug Metab Dispos 38:1967–75
   PubMed Web of Science ®Google Scholar
• Nishimuta H, Sato K, Mizuki Y, et al. (2011). Species differences in intestinal metabolic activities of cytochrome P450 substrates between cynomolgus monkeys and humans. Drug Metab Pharmacokinet 26:300–6
   PubMed Web of Science ®Google Scholar
• Pelkonen O. (2002). Human CYPs: in vivo and clinical aspects. Drug Metab Rev 34:37–46
   PubMed Web of Science ®Google Scholar
• Sahi J, Reyner EL, Bauman JN, et al. (2002). The effect of bergamottin on diazepam plasma levels and P450 enzymes in beagle dogs. Drug Metab Dispos 30:135–40
   PubMed Web of Science ®Google Scholar
• Shimada T, Mimura M, Inoue K, et al. (1997). Cytochrome P450-dependent drug oxidation activities in liver microsomes of various animal species including rats, guinea pigs, dogs, monkeys, and humans. Arch Toxicol 71:401–8
   PubMed Web of Science ®Google Scholar
• Takara K, Ohnishi N, Horibe S, Yokoyama T. (2003). Expression profiles of drug-metabolizing enzyme CYP3A and drug efflux transporter multidrug resistance 1 subfamily mRNAs in rat small intestine. Drug Metab Dispos 31:1235–9
   PubMed Web of Science ®Google Scholar
• Turpeinen M, Ghiciuc C, Opritoui M, et al. (2007). Predictive value of animal models for human cytochrome P450 (CYP)-mediated metabolism: a comparative study in vitro. Xenobiotica 37:1367–77
   PubMed Web of Science ®Google Scholar
• Wu S, Chen W, Murphy E, et al. (1997). Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. J Biol Chem 272:12551–9
   PubMed Web of Science ®Google Scholar
• Zhang QY, Ding X, Kaminsky LS. (1997). cDNA cloning, heterologous expression, and characterization of rat intestinal CYP2J4. Arch Biochem Biophys 340:270–8
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yao L, Lin J, et al. (2010). Lack of appreciable species differences in nonspecific microsomal binding. J Pharm Sci 99:3620–7
   PubMed Web of Science ®Google Scholar
• Zhou SF, Liu JP, Chowbay B. (2009). Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 41:89–295
   PubMed Web of Science ®Google Scholar
• Zuber R, Anzenbacherová E, Anzenbacher P. (2002). Cytochromes P450 and experimental models of drug metabolism. J Cell Mol Med 6:189–98
   PubMed Web of Science ®Google Scholar